35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022. YHCĐ 2024, 65 (CĐ 3 - Bệnh viện Phổi Trung ương). https://doi.org/10.52163/yhc.v65iCD3.1132.